{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:05:10Z","timestamp":1782471910109,"version":"3.54.5"},"reference-count":35,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,12,16]]},"published-print":{"date-parts":[[2025,3]]},"DOI":"10.2967\/jnumed.124.268318","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T18:45:28Z","timestamp":1738867528000},"page":"359-365","source":"Crossref","is-referenced-by-count":7,"title":["Safety, Dosimetry, and Feasibility of [<sup>68<\/sup>Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer"],"prefix":"10.2967","volume":"66","author":[{"given":"Liza","family":"Lindenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Pucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noella","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Chicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Feuerecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025030410451232000_66.3.359.1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1"},{"key":"2025030410451232000_66.3.359.2","unstructured":"American Cancer Society. Survival rates for prostate cancer. https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed August 5, 2024."},{"key":"2025030410451232000_66.3.359.3","doi-asserted-by":"publisher","DOI":"10.1016\/1078-1439(95)00002-Y"},{"key":"2025030410451232000_66.3.359.4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol."},{"key":"2025030410451232000_66.3.359.5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.semnuclmed.2023.07.005","article-title":"Standardized PSMA-PET imaging of advanced prostate cancer","volume":"54","author":"Seifert","year":"2024","journal-title":"Semin Nucl Med."},{"key":"2025030410451232000_66.3.359.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.01"},{"key":"2025030410451232000_66.3.359.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2025030410451232000_66.3.359.8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1050"},{"key":"2025030410451232000_66.3.359.9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025030410451232000_66.3.359.10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics."},{"key":"2025030410451232000_66.3.359.11","unstructured":"Highlights of prescribing information: Posluma (flotufolastat F 18) injection, for intravenous use. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216023s000lbl.pdf. Revised May 3, 2024. Accessed January 16, 2025."},{"key":"2025030410451232000_66.3.359.12","unstructured":"FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-second-PSMA-targeted-pet-imaging-drug-men-prostate-cancer. Updated May 27, 2021. Accessed January 16, 2025."},{"key":"2025030410451232000_66.3.359.13","unstructured":"FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer. U.S. Food and Drug Administration website. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer. Updated December 1, 2020. Accessed January 16, 2025."},{"key":"2025030410451232000_66.3.359.14","first-page":"13N","article-title":"FDA approves Pluvicto\/Locametz for metastatic castration-resistant prostate cancer","volume":"63","year":"2022","journal-title":"J Nucl Med."},{"key":"2025030410451232000_66.3.359.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics."},{"key":"2025030410451232000_66.3.359.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673"},{"key":"2025030410451232000_66.3.359.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.11.013"},{"key":"2025030410451232000_66.3.359.18","unstructured":"Muzio VRL Sacchetti L Fugazza L . Assessment of in\u00a0vivo biodistribution and treatment efficacy of 177Lu PSMA-R2 and 177Lu-PSMA-617 on mice bearing prostate cancer tumors. Paper presented at: European Association of Nuclear Medicine Annual Meeting. EJNMMI; 2019;46."},{"key":"2025030410451232000_66.3.359.19","first-page":"1319","article-title":"Safety and tolerability of 68Ga-PSMA-R2 as an imaging agent in patients with biochemical recurrence or metastatic prostate cancer","volume":"62","author":"Lindenberg","year":"2021","journal-title":"J Nucl Med."},{"key":"2025030410451232000_66.3.359.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.220715"},{"key":"2025030410451232000_66.3.359.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"2025030410451232000_66.3.359.22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JU.0000000000003598","article-title":"Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"210","author":"Jani","year":"2023","journal-title":"J Urol."},{"key":"2025030410451232000_66.3.359.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2025030410451232000_66.3.359.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0850-8"},{"key":"2025030410451232000_66.3.359.25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40658-018-0239-2","article-title":"Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients","volume":"6","author":"Sandgren","year":"2019","journal-title":"EJNMMI Phys."},{"key":"2025030410451232000_66.3.359.26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4103\/0971-5916.174563","article-title":"Estimation of radiation dose to patients from 18FDG whole body PET\/CT investigations using dynamic PET scan protocol","volume":"142","author":"Kaushik","year":"2015","journal-title":"Indian J Med Res."},{"key":"2025030410451232000_66.3.359.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.030"},{"key":"2025030410451232000_66.3.359.28","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oooo.2018.01.011","article-title":"Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET\/CT","volume":"125","author":"Klein Nulent","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"2025030410451232000_66.3.359.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265448"},{"key":"2025030410451232000_66.3.359.30","first-page":"292","article-title":"Examining absorbed doses of indigenously developed 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients at baseline and during course of peptide receptor radioligand therapy","volume":"36","author":"Kamaldeep","year":"2021","journal-title":"Cancer Biother Radiopharm."},{"key":"2025030410451232000_66.3.359.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178483"},{"key":"2025030410451232000_66.3.359.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22594-1"},{"key":"2025030410451232000_66.3.359.33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/RLU.0000000000004919","article-title":"PSMA radioligand therapy in prostate cancer: where are we and where are we heading?","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2025030410451232000_66.3.359.34","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.225250"},{"key":"2025030410451232000_66.3.359.35","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41391-021-00349-w","article-title":"Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Satapathy","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:47:17Z","timestamp":1741114037000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.2967\/jnumed.124.268318"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268318","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}